This year’s Molecular & Precision Medicine Tri-Con was attended by more than 1,000 people. International thought leaders gathered over 3 days to discuss the latest research, technologies, innovation and business models in implementing precision medicine, biomarkers and companion diagnostics, genomic medicine, and precision health; innovation and market access strategies for at-home diagnostics, point-of-care testing and molecular diagnostics for infectious diseases; liquid biopsy and advanced diagnostics for precision oncology, including Multi-Cancer Early Detection and Minimal Residual Disease testing; and emerging technologies for spatial biology and single-cell multiomics. The new track on Digital Medicine reflected on the future of precision medicine and added coverage of artificial intelligence, digital diagnostics and digital biomarkers, digital pathology, sensors and wearables.

As we celebrated the event’s 30th Anniversary, Cambridge Healthtech Institute once again took the leadership role of bringing together the life science community at the TRI-CON 2023.

The impressive audience at Molecular & Precision Medicine Tri-Con came together for invaluable networking opportunities with more than 50% of the attendees titled as a decision-maker from leading Biotech companies (58%) and Healthcare (10%). Industry leaders and key decision-makers representing 38 different countries and more than 500 unique organizations shared case studies, collaborated on best practices, and provided unique perspectives on poignant issues that the field currently faces.

2023年 出席者の内訳